But an anti-aging pill available for the masses is not around the corner. It might not even appear in our lifetime.
Category: NYSE:NVS
Big Pharma Should Accept Cap On Drug Price Increases
By capping price increases to inflation levels, PhRMA can show it cares about patients, drug costs and accessibility of its breakthroughs.
Novartis CEO Who Wanted To Bring Tech Into Pharma Now Explains Why It’s So Hard
We need to bring our best technology – biological and digital – and our most creative people together to work on this monumental challenge. One clear take-away from the Narasimhan interview: pharma is at the very earliest stages of figuring out how to…
The Demise Of A Once Promising Pancreatic Cancer Drug Is All Too Common
Companies as small as Nivien or as large as Pfizer find the chemical tools and run the experiments that prove or disprove medical hypotheses.
Think Generics Will Lower the Cost of Chemo? Think Again
Chemotherapy drugs have become ridiculously expensive. Fortunately, many expensive cancer drugs are going off patent soon, raising hopes that generic alternatives will significantly lower patients’ expenses. However, a recent study suggests our hopes m…
Novartis’ $4 Million Gene Therapy — Real Price Or A Negotiation Ploy?
We are in a wondrous age of medicine where CURES for certain types of cancer, rare diseases, blindness and other scourges are imminent. We now need to figure out how to pay for them.
In 2014 They Battled For Control. Now Pfizer’s Read And AstraZeneca’s Soriot In Different Places
Unfortunately, AstraZeneca’s revenue predictions have not lived up to Soriot’s promise.
Why Former Novartis CEO Joe Jimenez Joined A Microbiome Startup’s Board
uBiome, a San Francisco startup that sells commercial tests that use DNA sequencing to identify what microbes are in a person’s stool or, for one test, in the vagina, has raised $83 million from venture capitalists to fund an entrée into drug developme…
An Unwarranted Attack On Rare Disease Research
Hearing a parent agonize over the plight of their child who suffers from a rare disease is heart wrenching. For these families, research into rare disease drugs hasn’t come close to “reaching an extreme”.
The Agonizingly Slow Progress Against The Cancer That Killed Aretha Franklin
Our slow progress against pancreatic cancer is representative of the war on cancer writ large. Focus in on pancreatic cancer, and you see that there has been progress for patients with some subtypes for the disease. There are real reasons for hope that…
- 1
- 2
